Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.45 |
| ▸ | SOD1 | P00441 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 4/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18118971 | 0.88 | CYP3A4 (0.59) | CYP3A4CYP2C9CYP2C19SOD1LMNA | |
| SCHEMBL13118070 | 0.87 | CYP2C9 (0.49) | CYP3A4CYP2C9CYP2C19P2RY1SOD1 | |
| SCHEMBL26262687 | 0.87 | MAPT (0.52) | CYP2C9POLBKMT2AMMP2MMP3 | |
| SCHEMBL15576545 | 0.86 | CYP3A4 (0.57) | CYP3A4CYP2C9CYP2C19SOD1LMNA | |
| SCHEMBL31070675 | 0.84 | EPAS1 (0.46) | CYP3A4CYP2C9CYP2C19P2RY1 | |
| SCHEMBL25906303 | 0.83 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2C19P2RY1SOD1 | |
| SCHEMBL13216570 | 0.83 | CYP2C9 (0.51) | CYP3A4CYP2C9CYP2C19P2RY1POLB | |
| SCHEMBL5671239 | 0.82 | CYP2C9 (0.54) | CYP3A4CYP2C9CYP2C19SOD1LMNA | |
| SCHEMBL179310 | 0.82 | KCNN4 (0.50) | ACHENFE2L2HDAC4HDAC2HDAC8 | |
| SCHEMBL7938427 | 0.82 | MAPT (0.46) | POLBKMT2AACHENFE2L2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| US-9486422-B2 | Small molecule inhibitors of Mcl-1 and the uses of thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | CYP3A4 66/4885CYP2C9 175/4885CYP2C19 439/4885 |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | HCCS, HAVCR2, HDGF | CYP3A4 593/4885CYP2C9 1173/4885CYP2C19 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.